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Abstract
Introduction—Melanoma origin has always been a debated subject, as well as the role of 
adjacent melanocytic nevi. Epidemiological and histopathological studies point to melanomas 
arising either de novo or from a nevus.
Methods—Sixty-one melanomas found in association with a preexisting nevus were 
microdissected, after careful selection of cell subpopulations and submitted to Sanger sequencing 
of the BRAF, NRAS, C-KIT, PPP6C, STK19 and RAC1 genes. Each gene was evaluated twice in 
all samples by sequencing or by sequencing and another confirmation method, allele-specific 
fluorescent polymerase chain reaction (PCR) and capillary electrophoresis detection, or by 
SNaPshot Analysis. Only mutations confirmed via two different molecular methods or twice by 
sequencing were considered positive.
Results—The majority of cases presented concordance of mutational status between melanoma 
and the associated nevus for all 6 genes (40/60; 66.7%). Nine cases presented concomitant BRAF 
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and NRAS mutations, including one case, in which both the melanoma and the adjacent nevus 
harbored V600E and Q61K double mutations. In two cases, both melanoma and associated nevus, 
located on acral sites were BRAF mutated, including an acral lentiginous melanoma.
Conclusions—This is the largest nevus-associated melanoma series molecularly evaluated to 
our knowledge. The majority of melanomas and adjacent nevi in our sample share the same 
mutational profile, corroborating the theory that the adjacent nevus and melanoma are clonally 
related and that melanoma originated within a nevus.
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Introduction
Melanoma origin has always been a much debated subject, as well as the precursor role of 
pigmented lesions. Considering epidemiological and histological studies, melanoma may 
arise in association with a pre-existing nevus or de novo, without any associated lesion 1. It 
is controversial whether nevus-associated melanoma and de novo melanomas have a 
different prognosis 2–6, but a prior nevus-associated melanoma seems to be associated with a 
9-fold increased risk of presenting another nevus-associated melanoma 7. According to 
histopathological studies, the incidence of nevus-associated melanoma may vary from 20–
50% of all melanoma cases 2,5,8–18. Some authors suggest that benign melanocytic lesions 
could correspond to precursor lesions in melanoma genesis 19–23. Although the contiguity of 
nevus cells with melanoma, may provide some clues as to the etiopathogenesis of malignant 
melanoma, direct evidence of a causal relationship between the two is still lacking. The 
extent of genetic alterations has been shown to increase in parallel with the transitions from 
benign nevi to dysplastic nevi (DN) to melanoma, supporting multistep tumorigenesis 24. 
Further evidence that nevi could correspond to initial steps in melanomagenesis are the facts 
that nevi and melanoma share genetic alterations and BRAF mutated melanomas are more 
likely to be associated with multiple melanocytic nevi than BRAF-wild type 
melanomas 25,26.
Although molecular studies of melanoma and nevus present in contiguity suggested that 
melanoma and nevus cells could be clonally related 22,27–30, there is still no consensus for 
the nevus-to-melanoma progression model 31. While previous studies 22,27–32 differentiated 
nevus and melanoma cells using morphologic criteria only, it is important to point out that 
melanoma diagnosis may vary even among experts 33–35 and distinction of contiguous nevus 
cells and melanoma cells can be doubtful, especially in nevoid melanomas 35,36 and 
melanomas with adjacent dysplastic nevus 37,38. Thus possible selection bias of cell 
populations in the previous studies cannot be ruled out when considering clonality between 
melanoma and adjacent nevus. A combination of morphologic and immunohistochemistry 
markers would be the most reliable diagnostic method for melanoma 39. Therefore we 
sought to evaluate the presence of mutations in genes from well known melanomagenesis 
pathways, such as BRAF, NRAS, c-KIT, as well as new candidates as driver genes: RAC1, 
PPP6C and STK19 40, after careful selection of melanoma and nevus cell subpopulations in 
the largest series of nevus-associated melanomas, to our knowledge.
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Materials and Methods
Cases of melanoma found in histological association with a nevus were evaluated. All 
Formalin-fixed, paraffin-embedded (FFPE) samples studied were collected from the 
archives of a dermatopathology referral center in São Paulo-Brazil and the Hospital Clínic of 
Barcelona-Spain. The clinico-pathological data was extracted from the histopathological 
history. New slides stained with hematoxylin and eosin (HE) were independently evaluated 
by experienced dermatopathologists (N.M., M.M.S.S.E. and L.A.) and a dermatologist 
(D.S.). The nevus cytology criteria used for differentiation from melanoma cells were 
described elsewhere 41–43. Sixty-one cases (34 pairs from Brazil and 27 from Spain), which 
presented concordance for the diagnosis of nevus-associated melanoma by at least two of the 
evaluators and fulfilled the following criteria: undisputed distinction between nevus and 
melanoma and sufficient biological material from both melanoma and nevus cells for further 
analysis, were included.
All study participants gave their written informed consent to participate and the study was 
approved by the research ethic committees of the Federal University of São Paulo/
UNIFESP-EPM (number 188.713 of 24/01/2013) and the Hospital Clínic of Barcelona.
Immunohistochemistry
Available tumor tissue from 47 cases was stained using HMB-45 (Cell Marque, NL) and/or 
Ki-67 (Spring Bioscience, USA), Melan-A (Dako, DEN) as recommended by the 
manufacturer and slides were evaluated by two observers (D.S. and M.M.S.S.E.) in order to 
properly differentiate melanoma cells from nevus cells.
Laser Microdissection and DNA extraction
Contiguous nevus-melanoma specimens from FFPE archival tissue were sectioned (5 μm 
thick) on polyethylene naphthalate membranes (PEN Membrane slides®, LEICA, US) 
mounted on regular glass slides, according to manufacturer’s instructions, and stained with 
HE. Melanoma and nevus cells were microdissected using LEICA microdissector 
(LMD6500®/ LEICA Microsystems) according to previous marking on correspondent HE 
slides. DNA was extracted using the QIAmp DNA Micro kit (QIAGEN® Sample & Assay 
Technologies, Spain).
Mutational screening of BRAF, NRAS, C-KIT, PPP6C, STK19 and RAC1 by Sanger 
sequencing
BRAF (exons 11 and 15), NRAS (exons 2 and 3), c-KIT (exon 11), PPP6C (exon 7), RAC1 
(exon 2) and STK19 (exon 2) genes were amplified using nested PCR with 40–60ng of DNA 
for each reaction. PCR conditions were: denaturation at 95°C 5 min, 10 cycles (94°C 40sec, 
60°C–55°C 40 sec, 72°C 1 min), followed by 25 cycles (94°C 40sec, 57°C 40 sec, 72°C 1 
min) and extension at 72°C (10 min). The second PCR mixture was prepared using 1μl from 
the first PCR reaction. The nested PCR conditions were the same, except that the annealing 
temperature was 57°C. Nested primers were designed surrounding the exons (200–300bp 
long) with standard M13 forward (M13F: 5′ TGTAAAACGACGGCCAGT 3′) and M13 
reverse (M13R: 5′CAGGAAACAGCTATGACC 3′) tails being included on the internal 
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primers to standardize the capillary sequencing. Nucleotide sequences of nested primers are 
reported in Tables 1a and 1b. The PCR products were cleaned up using 6μL of Exo-SAP-IT 
(Applied Biosystems, CA, USA) and amplification was confirmed by 2% agarose gel 
electrophoresis. The entire amplicons were sequenced using both primers M13RF and 
M13R with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, CA, USA) 
on an ABI PRISM 3130xl automatic sequencer (Applied Biosystems, CA, USA) and 
analyzed using the SeqPilot 4.0.1 software (JSI Medical Systems).
BRAF p.V600E Mutational Analysis
The c.1799T>A (p.V600E) mutation was determined using allele-specific fluorescent PCR 
and capillary electrophoresis detection. Genomic DNA samples were amplified using 
primers described elsewhere 44. PCR conditions were: denaturation at 95°C for 5 min; 35 
cycles (94°C for 30 sec, 56°C for 40 sec, 72°C for 40 sec); extension at 72°C for 10 min. 
Amplicons were detected using capillary electrophoresis on ABI PRISM 3130xl and 
analyzed using GeneMapper Software (Applied Biosystems/Life Technologies, Grand 
Island, NY).
SNaPshot Analysis
The SNaPshot® Multiplex System was performed to confirm the results obtained by 
sequencing in the BRAF, NRAS and c-KIT genes45. We performed the multiplex PCR and 
extension PCR under the same conditions, using previously described primers 45.
Results
Table 2 summarizes the clinical characteristics for the 61paired cases (melanomas and their 
associated nevi) and their complete molecular screening results. Each gene was evaluated 
twice in all samples either by two different molecular methods or by Sanger sequencing 
twice and only confirmed mutations were considered as positive. The DNA extraction of 
nevus number 6 failed; therefore this pair was excluded from the analysis.
Clinical sample characteristics (Table 2)
Most melanomas were located on trunk and extremities (34/61 and 15/61 respectively). No 
mucosal melanomas were found. Most melanomas were superficial spreading melanomas 
(SSM) (39/61), one nodular melanoma, one acral lentiginous melanoma (ALM) and 18 were 
incipient melanomas which did not fulfill all the criteria for SSM. Two cases had incomplete 
pathological information.
Six associated nevi (10.0%) corresponded to congenital subtype, while 6 were junctional, 10 
compound and 3 intradermal common nevi and in 36 cases, no subtype could be specified. 
Only one of these latter showed signs of dysplasia (1/36). Twenty-one melanomas were in 
situ melanomas, and most invasive melanomas were thin melanomas, with a mean Breslow 
thickness of 0.75mm.
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Frequency of BRAF mutations in melanomas and associated nevi
BRAF exons 11 and 15 were evaluated in 60 paired cases. No mutation was detected in exon 
11. In exon 15, we detected the V600E (c.1799T>A) mutation in 46.6% (28/60) of 
melanomas and in 51.7% (31/60) of nevi. Regarding BRAF mutational status, most paired 
cases were concordant (78.3%; 47/60; Fig. 1). In 38.3% of cases a V600E-mutated 
melanoma had a preexisting V600E-mutated nevus (23/60). Among the discordant cases, a 
V600E-mutated melanoma had an adjacent BRAF-WT nevus in 8.3% of cases (5/60), while 
in 13% a V600E-mutated nevus was associated with a BRAF-WT melanoma (8/60).
The V600E mutation was confirmed in all cases using allele-specific fluorescent PCR. With 
this technique we could also estimate the percentage of mutated DNA present in each 
sample. Focusing on the concordant BRAF V600E mutated cases (23 pairs), we observed the 
same percentage of V600E mutation in 39% of these cases (9/23). However, 11 melanomas 
showed a higher percentage of V600E mutation than their associated nevi (48%; 11/23) and 
3 melanomas showed a lower percentage of V600E mutation in comparison with their 
associated nevi (13%; 3/23).
Frequency of NRAS mutations in melanomas and associated nevi
NRAS exons 2 and 3 were evaluated in 60 paired cases. No mutation was detected in exon 2, 
but in exon 3 we observed the Q61K (c.181C>A) mutation in 21.7% (13/60) of cases (Fig. 
1). Regarding NRAS mutational status, 85% of cases were concordant, being 78% (47/60) 
WT and 7% mutated (4/60). However, in 10% of cases we detected a mutated melanoma 
adjacent to a WT nevus (6/60) and the remaining 5% were wild-type melanomas associated 
with a mutated nevus (3/60). Additionally, we observed a double mutation in NRAS exon 3 
in two nevi (Table 2): in one case, melanoma and its associated nevus were both Q61K 
mutated but the nevus also harbored the Q70H (c.210A>T) variation. In the other case, an 
NRAS wild-type melanoma was associated with a Q61K mutated nevus that also harbored a 
D33D (c.99T>C) synonymous variation. These two nucleotide variations have not been 
previously reported.
Frequency of C-KIT, PPP6C, STK19 and RAC1 mutations in melanomas and associated 
nevi
No mutations were detected. All paired cases were wild-type for these genes.
Discussion
Driver mutations, being either the activation of an oncogene or the loss of a tumor 
suppressor allele, could trigger the establishment of a benign lesion. Thereafter the 
senescence program would control the tumor expansion, and another mutation would be 
necessary for tumor progression 30,46,47. Molecular analysis of melanomas and so called 
“precursor lesions” separately, so far point to alterations in critical genes of the MAPK and 
the PI3-Kinase-Akt pathways, as well as in genes involved in cell cycle regulation, as 
molecular pathways involved in melanoma genesis in the majority of cases 48,49. Indeed, 
most cases in this study show mutations in either BRAF or NRAS (67.2%; 41/61). The 
presence of BRAF V600E mutation in 31 of the studied nevi is in concordance with the 
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hypothesis that this mutation may be an early event in melanocytic tumorigenesis, even 
though alone it is not sufficient for progression to melanoma50–55. Most of the associated 
nevi included in this study were common melanocytic nevi. Since there is controversy 
regarding the diagnosis of dysplastic nevi 56,57, and since we only included cases in which 
distinction between melanoma and nevus cells was concordant among the observers, it may 
have led to a selection bias toward the inclusion of nevi with less dysplasia. A limitation 
observed by other authors 31. Unfortunately, since most of the nevi observed in our study 
were not dysplastic, even though the majority of our cases depicted the same mutational 
status between melanoma and nevus, no conclusion regarding the Clark multi-step 
melanoma progression can be made.
In our study the majority of cases (78.3%; 47/60; Table 2; Fig. 1) presented the same BRAF 
mutational status for both melanoma and nevus (mut/mut; WT/WT), being mutated in 48% 
(23/47) of concordant pairs, similar to previous studies 27,29,31,58. Considering these latter, 
the percentage of V600E mutation was similar in melanoma and nevus in 39% (9/23) of 
cases, while in 48% (11/23) the melanomas harbored a higher percentage of mutant cells 
compared to the adjacent nevus. The results support the hypothesis that the presence of 
V600E BRAF mutation confers an advantage for melanoma progression.
In a significant proportion of our cases (21.7%; 13/60) we observed that either the 
melanoma or the nevus was mutated while the counterpart was WT. It has been suggested 
that BRAF mutations are fully clonal in melanocytic nevi, so that it is expected that 
melanomas deriving from these nevi would be BRAF mutated as well 59. Therefore cases in 
which only the nevus was mutated favors the possibility of the absence of a clonal 
relationship between these two lesions. In cases where the BRAF mutation was only present 
in the melanoma, the possibility of the melanoma arising in the nevus cannot be excluded, 
since the melanoma may have later acquired the mutation or mutant parts of the associated 
nevus may have been overgrown by the melanoma and therefore may not have been 
accessible for analysis.
Recently Kakavand et al., after obtaining 100% concordance of BRAF mutational status 
between melanomas and associated nevi, suggested that a higher percentage of discordant 
melanomas and associated nevi obtained by Sanger sequencing, might be related to the 
technical difficulty of micro-dissecting out melanoma and admixed nevus cells. This could 
eventually explain why in case 47, both melanoma and nevus were Q61K mutated, while 
only the nevus was V600E mutated. Nevertheless cases with only the melanoma BRAF and 
NRAS mutated (cases 30 and 32) and the presence of a nevus with mutation in BRAF while 
the melanoma harbored mutation in NRAS (case 42), are more difficult to explain by 
technical differences among mutation detection techniques, and could highlight the fact that 
in some cases the contiguity of melanoma and nevus correspond to mere fortuitous collision.
Although it has been referred that BRAF V600 and NRAS Q61R 60 are among the most 
recurrent nucleotide substitutions in melanoma, all NRAS mutations observed in this study 
were Q61K, being this mutation described in melanomas and congenital nevi 61. Only one 
case in previous study 27–31 on melanoma and associated nevus described BRAF and NRAS 
mutations in the same lesion, while we found 9 cases with concomitant BRAF V600E and 
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NRAS Q61K mutations. A case, in which both melanoma and associated nevus harbored 
V600E and Q61K (case 35, Table 2; Fig. 2) and case 24, in which melanoma and nevus 
were V600E mutated, and only the melanoma acquired a Q61K mutation, further favors the 
possibility of melanoma and nevus cells being clonally related. BRAF and NRAS mutations 
are said to be mutually exclusive 49,62–66. Mutation of both BRAF and RAS, may not provide 
an additional significant growth/survival advantage (epistatic theory) 67 or is not compatible 
with cell survival (synthetic lethality theory) 68,69. Nevertheless there have been a few 
reports of primary melanomas harboring both mutations 70–73, with the hypothesis that these 
melanomas represent a mosaic with both mutations being mutually exclusive at a single cell 
level 70. This mosaic explanation may explain the recurrence of melanomas after BRAF 
inhibition 74. The presence of the Q61K mutation in both melanoma and nevus suggest that 
this mutation alone may not be sufficient for melanoma induction 75.
This is the first molecular study to evaluate the presence of cKIT among melanoma and 
associated nevus 22,27–32. KIT has been related to acral, mucosal and chronic sun exposure 
melanomas 53. We did not observe mutations in cKIT, not even among the Brazilian cases, 
even though solar exposure in Brazil is high. Interestingly, 2 cases located on acral sites 
were V600E mutated for both melanomas and nevi (Cases 50 and 61). One was an ALM 
(case 50) and the other was an in situ melanoma with no specified subtype (case 61). In the 
latter the nevus also harbored mutations in NRAS (D33D and Q61K), not present in the 
melanoma. Even though it was suggested that most acral melanomas would correspond to de 
novo melanomas 47, recently Lacruz et al described two cases of multiple BRAF-mutated 
acral melanomas. One of the cases presented a subungueal melanoma and a nevus-
associated melanoma on the toe, both BRAF mutated. The findings of our study corroborate 
the idea that nevus-associated melanomas located on acral sites would not be related to cKIT 
as de novo acral melanomas, but instead to BRAF, as nevus-associated melanomas from 
other sites, such as trunk 76.
Only two cases from our sample were located on the head, one wild-type (Case 1), while in 
the other, only the melanoma harbored a Q61K mutation (Case 4). Both cases were BRAF-
WT, concordant with the fact that BRAF is less frequent in high sun exposure areas, when 
compared to intermittent sun exposure areas 77. It has been suggested that there may be 
more than one pathway to melanoma 19,78. Roughly melanomas would be classified: 1) CSD 
melanomas (Chronic sun damage) related to chronic sun exposure, KIT or NRAS mutations 
and radial growth phase comprised of melanocytes arranged as solitary units with poor 
lateral circumscription; 2) non-CSD melanomas related to intermittent sun exposure, located 
on trunk and proximal extremities, association with nevus either directly adjacent or 
elsewhere, greater frequency of BRAF mutations and larger, slightly pigmented melanocytes 
arranged primarily in nests and that display upward intraepidermal scatter in their radial 
growth phase; 3) Acral melanomas with about 20% of mutations in KIT and 4) mucosal 
melanomas. The findings of the present study on 61 nevus-associated melanomas, that the 
majority of mutations observed affected BRAF, most cases were located on the trunk and 
proximal extremities and of the SSMM subtype and also the two acral nevus-associated 
melanomas were BRAF mutated, corroborate the idea that melanomas may have different 
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origins and that most nevus-associated melanomas may be classified amongst the non-CSD 
subtype.
Recently a list of genes with a statistically significant functional mutation burden was 
described after whole-genome sequencing. Among the most important were six well-known 
cancer genes (BRAF, NRAS, PTEN, TP53, p16INK4a and MAP2K1) and five new 
candidates for driver mutations, SNX31, TACC1, PPP6C, RAC1 and STK19 40,79, the latter 
three harboring recurrent mutations. Despite the high rate of amplification in our study, we 
didn’t find any mutations in the candidate driver genes (RAC1, STK19, PPP6C) evaluated. 
Mutations in RAC1, including the P29S mutation (UV-signature activating mutation)40, and 
in PPP6C are more frequently observed in sun-exposed melanomas. Even though our 
sample was mostly comprised of chronic or intermittent sun exposed melanomas, no 
mutation in these genes was detected.
Considering altogether the molecular results for the 6 genes evaluated (BRAF, NRAS, c-KIT, 
RAC1, PPP6C and STK19), the majority of cases in our study presented concordance of 
mutational status between melanoma and nevus (40/60; 66.7%).
When evaluating the hypothesis of clonality between melanoma and nevus, the correct 
sampling of cells is vital, especially in nevoid melanomas and melanomas adjacent to 
dysplastic nevi. We carefully selected melanoma and nevus cells allying morphologic 
criteria and immunohistochemistry, since none of these criteria is 100% specific in the 
diagnosis of melanoma 39 and have included cases where the distinction between melanoma 
and nevus was concordant among the observers. Therefore, after minimizing the selection 
bias for the subpopulation of melanoma and adjacent nevus cells, the majority of melanomas 
and adjacent nevus share the same mutational profile regarding the most relevant genetic 
hallmarks described in melanoma genesis, corroborating the theory that these lesions may be 
clonally related and that melanoma most probably originated within the nevus. Nevertheless, 
at least for some cases, the possibility of a fortuitous collision event cannot be ruled out 18. 
Even though we tested a broad panel of genes, the most frequently mutated genes in nevus-
associated melanoma remain related to the MAPK pathway.
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What is known about this topic?
Epidemiological and histopathological studies point to melanomas arising either de novo 
or associated with a nevus, but the role of the adjacent benign lesion remains to be 
elucidated.
What does this study add?
The majority of melanomas and adjacent nevi share the same mutational profile, 
corroborating the theory that melanoma and the adjacent nevus are clonally related and 
that melanoma originated within a nevus
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Figure 1. 
Comparison of mutational status between melanomas and associated nevi, adapted with the 
numbers of the present study from Tschandl et al.
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Figure 2. 
Melanomas and associated nevi: Dermoscopy (a), Haematoxylin-eosin (b) and laser 
microdissection (c) (d) of case 35, melanoma and associated nevus both mutated for BRAF 
V600E and NRAS Q61K. Dermoscopy (e), HE (f) and laser microdissection (g)(h) of case 
50, acral lentiginous melanoma and adjacent nevus both BRAF V600E mutated. 
Dermoscopy (i), HE (j) and laser microdissection (k)(l) of case 53, superficial spreading 
melanoma and adjacent nevus both BRAF V600E mutated. (c) and (k) Delimitation of 
melanoma cells in red and naevus cells in green. (g) Delimitation of melanoma cells in green 
and naevus cells in red. (d), (h) and (l) show the empty areas of melanoma and nevus cells 
after laser dissection.
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